299 related articles for article (PubMed ID: 33333121)
1. Lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition.
Suzuki Y; Onuma H; Sato R; Sato Y; Hashiba A; Maeki M; Tokeshi M; Kayesh MEH; Kohara M; Tsukiyama-Kohara K; Harashima H
J Control Release; 2021 Feb; 330():61-71. PubMed ID: 33333121
[TBL] [Abstract][Full Text] [Related]
2. Lipid nanoparticle-based ribonucleoprotein delivery for in vivo genome editing.
Onuma H; Sato Y; Harashima H
J Control Release; 2023 Mar; 355():406-416. PubMed ID: 36773957
[TBL] [Abstract][Full Text] [Related]
3. [Genome editing in plants directed by CRISPR/Cas ribonucleoprotein complexes].
Li X; Shi W; Geng LZ; Xu JP
Yi Chuan; 2020 Jun; 42(6):556-564. PubMed ID: 32694114
[TBL] [Abstract][Full Text] [Related]
4. Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication.
Zhang J; Zhang Y; Khanal S; Cao D; Zhao J; Dang X; Nguyen LNT; Schank M; Wu XY; Jiang Y; Ning S; Wang L; El Gazzar M; Moorman JP; Guo H; Yao ZQ
J Med Virol; 2023 Jul; 95(7):e28952. PubMed ID: 37455550
[TBL] [Abstract][Full Text] [Related]
5. Advances with using CRISPR/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus.
Moyo B; Bloom K; Scott T; Ely A; Arbuthnot P
Virus Res; 2018 Jan; 244():311-320. PubMed ID: 28087399
[TBL] [Abstract][Full Text] [Related]
6. Packaging and Uncoating of CRISPR/Cas Ribonucleoproteins for Efficient Gene Editing with Viral and Non-Viral Extracellular Nanoparticles.
Mazurov D; Ramadan L; Kruglova N
Viruses; 2023 Mar; 15(3):. PubMed ID: 36992399
[TBL] [Abstract][Full Text] [Related]
7.
Kayesh MEH; Hashem MA; Kohara M; Tsukiyama-Kohara K
Front Microbiol; 2022; 13():953218. PubMed ID: 35847068
[TBL] [Abstract][Full Text] [Related]
8. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas.
Yang YC; Yang HC
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062208
[TBL] [Abstract][Full Text] [Related]
9. [Application of clustered regularly interspaced short palindromic repeats- associated protein 9 gene editing technology for treatment of HBV infection].
Wang YD; Liang QF; Li ZY; Zhao CY
Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):860-864. PubMed ID: 30616324
[TBL] [Abstract][Full Text] [Related]
10. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA.
Ohno M; Otsuka M; Kishikawa T; Yoshikawa T; Takata A; Koike K
World J Gastroenterol; 2015 Jun; 21(23):7084-8. PubMed ID: 26109795
[TBL] [Abstract][Full Text] [Related]
11. A stable DNA-free screening system for CRISPR/RNPs-mediated gene editing in hot and sweet cultivars of Capsicum annuum.
Kim H; Choi J; Won KH
BMC Plant Biol; 2020 Oct; 20(1):449. PubMed ID: 33004008
[TBL] [Abstract][Full Text] [Related]
12. LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea.
Mirjalili Mohanna SZ; Djaksigulova D; Hill AM; Wagner PK; Simpson EM; Leavitt BR
J Control Release; 2022 Oct; 350():401-413. PubMed ID: 36029893
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Hepatitis B Virus with the Help of CRISPR/Cas9 Technology.
Noor S; Rasul A; Iqbal MS; Ahmed B; Akash MSH; Qadir MI
Crit Rev Eukaryot Gene Expr; 2020; 30(3):273-278. PubMed ID: 32749114
[TBL] [Abstract][Full Text] [Related]
14. Genome editing of mutant KRAS through supramolecular polymer-mediated delivery of Cas9 ribonucleoprotein for colorectal cancer therapy.
Wan T; Chen Y; Pan Q; Xu X; Kang Y; Gao X; Huang F; Wu C; Ping Y
J Control Release; 2020 Jun; 322():236-247. PubMed ID: 32169537
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells.
Bloomer H; Khirallah J; Li Y; Xu Q
Adv Drug Deliv Rev; 2022 Feb; 181():114087. PubMed ID: 34942274
[TBL] [Abstract][Full Text] [Related]
16. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease.
Kennedy EM; Bassit LC; Mueller H; Kornepati AVR; Bogerd HP; Nie T; Chatterjee P; Javanbakht H; Schinazi RF; Cullen BR
Virology; 2015 Feb; 476():196-205. PubMed ID: 25553515
[TBL] [Abstract][Full Text] [Related]
17. Delivery of CRISPR-Cas12a Ribonucleoprotein Complex for Genome Editing in an Embryogenic Citrus Cell Line.
Fang H; Culver JN; Niedz RP; Qi Y
Methods Mol Biol; 2023; 2653():153-171. PubMed ID: 36995625
[TBL] [Abstract][Full Text] [Related]
18. Genome editing in potato via CRISPR-Cas9 ribonucleoprotein delivery.
Andersson M; Turesson H; Olsson N; Fält AS; Ohlsson P; Gonzalez MN; Samuelsson M; Hofvander P
Physiol Plant; 2018 Dec; 164(4):378-384. PubMed ID: 29572864
[TBL] [Abstract][Full Text] [Related]
19. Finely tuned ionizable lipid nanoparticles for CRISPR/Cas9 ribonucleoprotein delivery and gene editing.
Im SH; Jang M; Park JH; Chung HJ
J Nanobiotechnology; 2024 Apr; 22(1):175. PubMed ID: 38609947
[TBL] [Abstract][Full Text] [Related]
20. [Antiviral Activity of CRISPR/Cas9 Ribonucleoprotein Complexes on a Hepatitis B Virus Model In Vivo].
Kostyusheva AP; Brezgin SA; Ponomareva NI; Goptar IA; Nikiforova AV; Gegechkori VI; Poluektova VB; Turkadze KA; Sudina AE; Chulanov VP; Kostyushev DS
Mol Biol (Mosk); 2022; 56(6):884-891. PubMed ID: 36475475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
